论文部分内容阅读
目的:探讨血浆白细胞介素(IL-17)在慢性阻塞性肺疾病(COPD)综合评估中的作用。方法:取30例健康体检者(健康对照组)、按照GOLD2011综合评估标准入选COPD ABCD级患者各30例,采用双抗体酶联免疫吸附测定(ELISA)法测定血浆中IL-17水平。并对全部研究对象进行肺功能检查,计算出一秒钟用力呼气容积占用力肺活量比值(FEV1%/FVC)及进行CAT问卷评分。结果:COPD各级别血浆IL-17水平及CAT评分与正常对照组存在统计学差异,除A级和B级,B,C,D各级两两之间及CAT评分再各级别两两之间均存在统计学差异(P<0.05),且随着级别的恶化两指标水平总体上呈上升趋势。各级别血浆IL-17水平与CAT评分均存在正相关。结论:血浆IL-17水平可作为COPD患者综合评估的全身炎症水平严重程度指标。
Objective: To investigate the role of plasma interleukin (IL-17) in the comprehensive assessment of chronic obstructive pulmonary disease (COPD). Methods: Thirty healthy subjects (healthy control group) were enrolled in this study. Thirty patients with COPD were enrolled in this study according to the criteria of GOLD2011 comprehensive evaluation. The level of IL-17 in plasma was determined by enzyme linked immunosorbent assay (ELISA). Pulmonary function tests were performed on all subjects, and FEV 1% / FVC was calculated for forced expiratory volume in one second and CAT questionnaire was scored. Results: Plasma levels of IL-17 and CAT at COPD were significantly different from those in normal controls except for grade A and grade B, grade B, grade C and grade D, grade 2 and grade 2 There were statistical differences (P <0.05), and with the level of deterioration of the two indicators generally showed an upward trend. There was a positive correlation between plasma IL-17 level and CAT score at all levels. Conclusion: Plasma IL-17 levels can be used as a comprehensive index of COPD patients with systemic inflammation severity indicators.